fbpx

Brain Cancer

Frontal Lobe Astrocytoma

Male, 38 years

Patient Internal 146903545

ICD-10 code

C71.1 Malignant Neoplasm of the Frontal Lobe

Diagnosis (Incl. Metastases/Stage) and Year

June 2019
High-grade Malignant Astrocytoma of the Frontal Lobe G2, IDH1 mutated. March 2020 – Tumour Recurrence: Brain Anaplastic Astrocytoma G3, IDH1 and ATRX mutated, Ki67 – 20%. Recraniotomy, Tumour Removal (08-04-2020).

Previous Treatment

Surgery (craniotomy), chemotherapy (Temozolomide).

Prognosis and Survival Expectation

The prognosis remains poor, with a median survival of 33 months from diagnosis.

Treatment Provided

Autologous DCV (10 doses) and CIK (4 doses) over a period of 14 months.
Additionally, the patient received nasal drops of exosomes with Paclitaxel.

Patient Survival/Condition and Year
Date of Review: 15/10/2023

The patient is alive (now 52 months since diagnosis) with stable disease.
It can be concluded that the addition of Immunotherapy, alongside Surgery and Chemotherapy, has extended
the patient’s survival by about 1 and a half years so far, compared with median survival.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.